CliniGuide
Develops digital clinical decision support tools for complex critical care settings like cancer and intensive care.
Website: https://cliniguide.ai
Cover Block
PUBLIC
| Attribute | Value |
|---|---|
| Name | CliniGuide |
| Tagline | Develops digital clinical decision support tools for complex critical care settings like cancer and intensive care. |
| Headquarters | Montreal, Quebec |
| Founded | 2016 |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | Seed |
Links
PUBLIC The following links provide direct access to the company's primary online presence and product interface.
- Website: https://cliniguide.ai
- LinkedIn: https://ca.linkedin.com/company/cliniguide-cdss
Executive Summary
PUBLIC
CliniGuide is a Montreal-based healthtech startup building digital clinical decision support tools for high-stakes oncology and intensive care workflows, a niche where data fragmentation and complex team coordination create persistent operational friction [Esplanade Québec]. Founded in 2016, the company has developed a SaaS product that consolidates patient data into intelligent dashboards, aiming to surface predictive insights and streamline the preparation for multidisciplinary care meetings [Esplanade Québec]. The core differentiation appears to rest on a deep workflow integration for these specific, complex care settings rather than a general-purpose analytics layer. Public leadership is anchored by CEO Christophe Vergne, who brings over 25 years of healthcare industry experience to the role [Christophe VERGNE - CliniGuide Inc. | LinkedIn, 2026].
Capitalization is not publicly disclosed; investors should request the cap table directly. Third-party estimates place revenue around $427,775 with a valuation of approximately $1.4 million, but these figures are unverified and should be treated with caution [Prospeo]. The company participated in Esplanade Québec's Accélération program for health-impact ventures in 2024, which serves as a recent signal of activity within the Quebec ecosystem [Esplanade Québec, 2024]. Over the next 12-18 months, the key watchpoints are the announcement of a first institutional funding round, the disclosure of initial pilot or customer deployments in hospital networks, and any expansion of the product footprint beyond its current focus on cancer and ICU care.
Data Accuracy: YELLOW -- Core product description and CEO background are confirmed; financial and funding data are from a single unverified source.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding | Seed |
Company Overview
PUBLIC
CliniGuide was founded in 2016 in Montreal, Quebec, with a focus on developing clinical decision support tools for high-acuity medical environments [Esplanade Québec]. The company's public profile centers on its participation in the 2024 cohort of Esplanade Québec's Accélération program, a health-focused startup support initiative, which serves as its most recent verifiable milestone [Esplanade Québec, 2024].
Christophe Vergne is identified as the Chief Executive Officer of CliniGuide Inc. [RocketReach]. His LinkedIn profile notes over 25 years of experience in the healthcare industry, with an educational background from IAE Toulouse and Ecole de Management de l'Université Toulouse 1 Capitole [Christophe VERGNE - CliniGuide Inc. | LinkedIn, 2026]. Details regarding other founders, the company's legal structure, or earlier operational milestones are not publicly documented in the available sources.
Data Accuracy: YELLOW -- Company description and CEO role confirmed by Esplanade Québec and RocketReach. Founding year and program participation are single-source claims.
Product and Technology
MIXED
CliniGuide’s product is defined by its focus on high-stakes clinical workflows, specifically in oncology and intensive care. The company develops digital clinical decision support tools that consolidate and analyze patient data into intelligent dashboards, with the stated goal of surfacing critical and predictive information to clinicians [Esplanade Québec]. This is not a general-purpose analytics platform; the design is explicitly for complex, critical care settings where treatment decisions are multidisciplinary and data-heavy.
The core functionality centers on preparing and running multidisciplinary team (MDT) meetings, a common but administratively burdensome process in cancer care. The product appears to aggregate disparate patient data points into a unified view, aiming to improve the quality and safety of personalized treatment plans [Esplanade Québec]. The company’s website, which presents itself as a dashboard portal, suggests a working, customer-facing application is in use, though specific features and interface details are not publicly documented [cliniguide.ai].
From the available descriptions, the technological differentiation rests on workflow integration for specialized care teams rather than on a novel underlying AI model. The value proposition is operational: reducing cognitive load and administrative friction for clinicians managing complex cases. The technology stack is not disclosed, but the product’s nature implies backend systems for health data integration, a rules or analytics engine for surfacing insights, and a dashboard layer for visualization.
Data Accuracy: YELLOW -- Product claims are consistent across the company’s profile and website, but technical specifications, deployment details, and user interface are not publicly visible.
Market Research
PUBLIC The market for clinical decision support systems (CDSS) is expanding beyond general-purpose alerts into specialized, high-stakes environments where the cost of error is measured in lives, not just dollars.
While specific TAM/SAM figures for oncology and intensive care unit CDSS are not publicly available from CliniGuide's sources, the broader digital health and clinical IT market provides context. The global clinical decision support systems market was valued at $5.9 billion in 2023 and is projected to grow at a compound annual growth rate of 10.2% through 2030, according to a report by Grand View Research [Grand View Research, 2024]. The oncology information systems segment, a key adjacent market, is itself a multi-billion dollar category driven by the complexity of cancer care pathways and the rise of precision medicine.
Demand for solutions like CliniGuide's is anchored in persistent systemic pressures within hospital critical care. Key drivers include the need to reduce clinical variation and medical errors, a well-documented challenge in complex care coordination [The Joint Commission]. The push for value-based care models creates financial incentives for tools that improve outcomes and reduce costly complications or readmissions. Furthermore, the proliferation of patient data from electronic health records, genomics, and continuous monitoring devices has created an information overload problem, making intelligent data synthesis and predictive analytics a practical necessity for clinicians [Health Affairs, 2023].
Regulatory and macro forces present both tailwinds and implementation hurdles. In the United States, the 21st Century Cures Act promotes interoperability and patient data access, which could facilitate the integration of third-party decision support tools [U.S. Congress, 2016]. However, the market is also shaped by stringent medical device regulations; software intended to inform clinical diagnosis or treatment decisions may be classified as a SaMD (Software as a Medical Device) and require clearance from bodies like the FDA or Health Canada, adding significant time and cost to commercialization. In Quebec and Canada, provincial healthcare procurement processes can be lengthy, favoring incumbents with established government contracts.
| Metric | Value |
|---|---|
| Clinical Decision Support Systems Market (Global) | 5.9 $B (2023) |
| Projected CAGR (2024-2030) | 10.2 % |
| Oncology Information Systems Segment | (analogous market) Multi-$B |
The underlying market growth is robust, but the relevant segment for CliniGuide,specialized CDSS for complex care,is a fraction of the total, competing on clinical workflow integration rather than broad IT spend.
Data Accuracy: YELLOW -- Market sizing is based on third-party analyst reports for analogous segments; specific TAM for the company's niche is not confirmed.
Competitive Landscape
MIXED, CliniGuide operates at the intersection of two high-stakes, high-complexity healthcare segments where the competitive map is defined by large-scale incumbents, specialized software vendors, and a new wave of AI-native clinical intelligence platforms.
The analysis proceeds with a segment-based mapping of the competitive environment.
The oncology and intensive care software market is bifurcated. On one side are the large-scale electronic health record (EHR) and clinical management suite vendors, such as Epic, Cerner, and McKesson, which offer embedded oncology modules and critical care dashboards as part of broad enterprise contracts [McKesson]. Their primary advantage is incumbency within hospital IT stacks, creating significant switching costs. On the other side are specialized, best-of-breed clinical decision support (CDS) and workflow tools. These include oncology-specific platforms like Flatiron Health (owned by Roche) and Varian's suite, which focus on data aggregation and real-world evidence, and newer AI-driven CDS companies like Abridge, which focus on ambient documentation and conversation-based support [Abridge, 2025]. CliniGuide's stated focus on dashboards for multidisciplinary team (MDT) meeting preparation suggests it is competing in this latter, specialized tier, aiming to be a workflow layer atop, rather than a replacement for, core EHR systems.
CliniGuide's potential defensible edge rests on two pillars: domain-specific workflow design and a Quebec-first, possibly French-language, distribution path. The product's explicit design for cancer and ICU MDT meetings indicates a focus on a specific, high-value clinical process that broader platforms may address only generically. This workflow specialization could create initial user stickiness. Furthermore, being headquartered in Montreal and participating in local accelerators like Esplanade Québec provides a potential beachhead in the Quebec healthcare system, a market with distinct procurement pathways and language requirements that could deter larger U.S.-based competitors initially. However, this edge is perishable. Workflow knowledge can be replicated by larger vendors with deeper R&D budgets, and geographic moats are thin if the product lacks deep, proprietary data integrations or regulatory clearances that are costly to duplicate.
The company's most significant exposure is its lack of visible scale and capital relative to both incumbents and well-funded challengers. Without disclosed funding or named customer deployments, it is difficult to assess its capacity to invest in the commercial expansion, regulatory compliance (e.g., FDA clearance for decision support algorithms), and interoperability engineering required to move beyond a regional pilot. A competitor like Abridge, which has raised significant venture capital and partners directly with large health systems, could extend its ambient AI platform into the pre-meeting data synthesis space, leveraging its existing integration footprint and capital advantage [Abridge, 2025]. CliniGuide also cannot easily enter the adjacent market of patient-facing tools or population health analytics, which are capital-intensive plays dominated by scaled players.
The most plausible 18-month scenario is one of consolidation within niche CDS segments. If CliniGuide successfully demonstrates improved clinical outcomes or time savings in MDT meetings within a cluster of Quebec hospitals, it becomes an attractive regional acquisition target for a larger healthcare IT vendor seeking a localized clinical workflow asset. The "winner" in this scenario would be a company like McKesson or a mid-tier EHR vendor looking to bolster its oncology offering without building from scratch. Conversely, the "loser" would be CliniGuide if it fails to convert its specialized workflow into a commercially scalable product beyond a single region, remaining a feature rather than a platform as better-funded competitors build or buy similar capabilities.
Data Accuracy: YELLOW, Competitive mapping is inferred from the company's described product focus and general market knowledge; no direct competitor comparisons are available from cited sources.
Opportunity
PUBLIC The prize for CliniGuide is a central, reimbursable software layer within the high-stakes, high-cost workflows of oncology and intensive care, where clinical decisions directly impact patient survival and hospital economics.
The headline opportunity is to become the standard operating system for multidisciplinary tumor boards and critical care rounds in North American hospitals. This outcome is reachable because the company's stated product focus,consolidating disparate patient data into predictive dashboards for complex care meetings,addresses a documented, persistent pain point in clinical workflow. The shift towards value-based care and bundled payment models in oncology, for example, creates financial pressure for hospitals to standardize and optimize treatment pathways. A tool that demonstrably improves coordination and reduces variation could transition from a discretionary purchase to a reimbursable cost-of-care improvement. The evidence that this is more than an aspirational goal lies in the company's specific targeting of cancer and ICU settings, which are among the most data-intensive and protocol-driven areas in medicine, and its participation in a structured acceleration program for health impact companies in Quebec [Esplanade Québec, 2024].
Growth would likely follow one of several concrete, named paths. The following scenarios outline plausible routes to scale.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Provincial Anchor in Quebec | CliniGuide becomes the recommended or procured CDS tool for oncology across the Quebec public health network (CISSS/CIUSSS). | A successful pilot at a major Montreal cancer centre leads to a regional procurement contract. | The company is based in Montreal and participated in a Quebec-focused health accelerator, indicating established local networks and understanding of the provincial system [Esplanade Québec, 2024]. Public healthcare systems often pilot and scale solutions locally first. |
| Specialty-Focused Land-and-Expand | The company achieves deep penetration in community oncology clinics, starting with a niche like breast or lung cancer, then expanding to other tumor types and adjacent specialties. | A partnership with a specialty-focused electronic health record (EHR) vendor or a large oncology practice management group. | Oncology is highly specialized, and tools often gain adoption by dominating a specific sub-field. Community clinics, which may lack the resources of large academic hospitals, are a prime market for efficiency tools. |
Compounding for CliniGuide would manifest as a clinical data and workflow moat. Each new hospital or clinic deployment adds more patient cases and treatment histories to its system (assuming data is aggregated and anonymized for model training). This growing dataset could improve the predictive accuracy and clinical relevance of its dashboards, making the tool more valuable for subsequent customers. Furthermore, as clinicians across different institutions use the same platform to prepare for and conduct multidisciplinary meetings, a network effect around shared protocols and best practices could emerge, increasing switching costs. The company's product description, which emphasizes surfacing predictive information, suggests this data flywheel is a core part of its design intent [Esplanade Québec].
The size of the win, should a growth scenario play out, can be framed by looking at comparable companies. For instance, publicly traded Veeva Systems, which provides cloud software for life sciences, commands a market capitalization in the tens of billions, though its focus is commercial and R&D. A more direct, albeit private, comparable might be a company like Abridge, which focuses on AI-powered clinical documentation and decision support and raised a $150 million Series C at a $850 million valuation in 2025 [Abridge, 2025]. While Abridge's approach is broader, it demonstrates the valuation potential for AI-native clinical workflow tools that achieve scale. If CliniGuide successfully executes the "Provincial Anchor" scenario and expands beyond Quebec, it could aim for a valuation trajectory in the high hundreds of millions, contingent on demonstrating recurring revenue, clinical outcomes data, and a clear expansion roadmap (scenario, not a forecast).
Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated product focus and participation in a local accelerator. Growth scenarios are plausible extrapolations but lack public confirmation of pilots, partnerships, or commercial traction.
Sources
PUBLIC
[Esplanade Québec] CliniGuide Profile | https://esplanade.quebec/portfolio_page/cliniguide/
[cliniguide.ai] CliniGuide - Dashboard | https://cliniguide.ai
[RocketReach] Christophe Vergne - Chief Executive Officer at CliniGuide Inc. | https://rocketreach.co/christophe-vergne-email_37873672
[Christophe VERGNE - CliniGuide Inc. | LinkedIn, 2026] Christophe Vergne Profile | https://ca.linkedin.com/in/christophevergne
[Prospeo] CliniGuide revenue and valuation | https://prospeo.io/c/cliniguide-revenue
[Esplanade Québec, 2024] 8 entreprises d’impact en santé joignent le programme Accélération | https://esplanade.quebec/8-nouvelles-entreprises-impact-sante-rejoignent-programme-acceleration-sante-2024/
[Grand View Research, 2024] Clinical Decision Support Systems Market Size Report | https://www.grandviewresearch.com/industry-analysis/clinical-decision-support-systems-market
[The Joint Commission] Sentinel Event Data 2022 Annual Review | https://www.jointcommission.org/resources/patient-safety-topics/sentinel-event/sentinel-event-data/
[Health Affairs, 2023] The Promise And Peril Of AI In Clinical Decision Support | https://www.healthaffairs.org/doi/10.1377/hlthaff.2023.00445
[U.S. Congress, 2016] 21st Century Cures Act | https://www.congress.gov/114/plaws/publ255/PLAW-114publ255.pdf
[McKesson] Oncology Clinical Management Technology | https://www.mckesson.com/specialty/technology-solutions-specialty-practices/oncology-clinical-management-technology/
[Abridge, 2025] Bringing Clinical Decision Support Into the Flow of Clinical Conversations | https://www.abridge.com/blog/clinical-decision-support
Articles about CliniGuide
- CliniGuide Consolidates the Cancer and ICU Patient Dashboard — The Montreal startup's clinical decision support software aims to unify fragmented data for multidisciplinary teams in high-stakes care.